Published 2 days ago • loading... • Updated 2 days ago

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line ...

Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated

Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated

2 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left1Leaning Right0Center0Last Updated2 days agoBias Distribution

100% Left

100% Left

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news in 2 days ago on Monday, February 2, 2026.

Sources are mostly out of (0)